Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
← catalyst calendarNCT06051617 · readout ≤ 1,473 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
318estimated
Sites
211
Countries
Argentina, Australia, Austria +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-07 | actual | When the study began enrolling |
| Primary completion | Aug 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Biliary Cholangitis
Interventions
- Drug: Seladelpar — also filed as Livdelzi®
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFEvent Free Survival (EFS)
measured 36 months
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed